A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

NCT02681094 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

905

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Inadequate Glycaemic Control

Interventions

DRUG: Dapagliflozin
DRUG: Placebo for Dapagliflozin
DRUG: Saxagliptin
DRUG: Placebo for Saxagliptin

Sponsor

AstraZeneca